Fanconi anemia (FA) is a rare recessive DNA repair deficiency resulting from mutations in one of at least 22 genes. Two-thirds of FA families harbor mutations in FANCA. To genotype patients in the International Fanconi Anemia Registry (IFAR) we employed multiple methodologies, screening 216 families for FANCA mutations. We describe identification of 57 large deletions and 261 sequence variants, in 159 families. All but seven families harbored distinct combinations of two mutations demonstrating high heterogeneity. Pathogenicity of the 18 novel missense variants was analyzed functionally by determining the ability of the mutant cDNA to improve the survival of a FANCA-null cell line when treated with MMC. Overexpressed pathogenic missense variants were found to reside in the cytoplasm, and nonpathogenic in the nucleus. RNA analysis demonstrated that two variants (c.522G > C and c.1565A > G), predicted to encode missense variants, which were determined to be nonpathogenic by a functional assay, caused skipping of exons 5 and 16, respectively, and are most likely pathogenic. We report 48 novel FANCA sequence variants. Defining both variants in a large patient cohort is a major step toward cataloging all FANCA variants, and permitting studies of genotype-phenotype correlations.
(MIM# 179617), can also cause the disease, resulting in a total of 22 FA genes reported thus far (Knies et al., 2017; Kottemann & Smogorzewska, 2013; Mamrak, Shimamura, & Howlett, 2016; Rickman et al., 2015; Wang & Smogorzewska, 2015) . The underlying defect in FA patients is the inability to repair DNA interstrand crosslinks (ICLs), although many proteins encoded by the FA genes have functions outside of ICL repair (Boersma et al., 2015; Schlacher et al., 2011; Schlacher, Wu, & Jasin, 2012; West et al., 2015; Xu, et al., 2015) Two-thirds of FA patients harbor pathogenic variants in FANCA, which makes it the most frequently mutated FA gene, while 20% of patients carry mutations in FANCC or FANCG, and causative mutations in the other 19 FA genes account for 0.1%-4% of cases per gene (Wang & Smogorzewska, 2015) . FANCA variants include singlenucleotide variations, small insertions and deletions (indels), and large deletions. FANCA variants are largely private, except for three founder mutations: exon12-31del, c.295C > T (p.Q99*), and exon15del in South Afrikaner (Tipping et al., 2001 ), Spanish Gypsy (Callen et al., 2005; Castella et al., 2011) , and Tunisian (Amouri et al., 2014) families, respectively. In addition there are two frequently observed mutations across ethnic groups: c.3788_3790delTCT in exon 38 and c.1115_1118delTTGG in exon 13 (Levran et al., 1997) (FA MutDB: https://www2.rockefeller.edu/fanconi//). Twenty to forty percent of FANCA mutations are large deletions which were found, primarily, by multiplex ligation probe analysis (MLPA) (Castella et al., 2011; Centra et al., 1998; Flynn et al., 2014; Levran, Doggett, & Auerbach, 1998; Moghrabi et al., 2009; Morgan, Tipping, Joenje, & Mathew, 1999) . Our recent study scanning for large deletions in the entire gene and 200 kb 5 ′ and 3 ′ to the gene regions by high-resolution aCGH (Comparative Genomic Hybridization) indicates that nearly half of the FANCA large deletions extend beyond boundaries of the gene (Flynn et al., 2014) . In addition, because the FANCA gene is large, with 43 exons, it harbors complex heterogeneity of mostly private mutations. As a result, many patients are left with uncharacterized diseasecausing FANCA mutations.
Complete molecular diagnosis of the disease-causing gene and specific pathogenic variants is required for confirmation of an FA diagnosis and understanding of genotype-phenotype correlations. Molecular diagnosis is also critical for detection of mutation carriers, identification of appropriate donors for bone marrow transplantation, counseling of families, and exploring novel therapeutic interventions.
We present here a summary of screening results from 216 FA families, and characterization of both variants in 159 FANCA families.
We employed high-throughput sequencing strategies for detection of variants, and MLPA, aCGH, and SNP arrays for large deletions. In situations where pathogenicity was uncertain, we performed functional evaluation to obtain a more accurate characterization of potentially pathogenic variants. This work highlights the importance of a multipronged approach for identifying all causative mutations in FA patients.
METHODS
Further details on the sequencing methods and analysis, and additional methods are presented online as Supplemental Material. 
Study subjects
Genomic
High-throughput Sanger sequencing
Forty-nine amplicons ranging in size from 222-740 bp were designed to cover the exons and the flanking regions of FANCA (NG_011706.1, NM_000135.3). We adopted published ClinSeq methodologies (Biesecker et al., 2009 ) for high-throughput Sanger sequencing of genomic DNA samples from 179 FANCA families. PCR products were subjected to bidirectional Sanger sequencing. Sequence data from ∼19,000 sequence reads was analyzed to identify sequence variants and to find rare, likely pathogenic variants. Common polymorphic variants were removed based on their frequency in the 1000 Genomes Project (1000G), NHLBI Exome Sequencing Project (ESP6500), Exome Aggregate Consortium (ExAC), and dbSNP databases. Further details are reported in the online Supplementary Material.
TruSeq Custom Amplicon capturing and sequencing and analysis
TruSeq Custom Amplicon design (Illumina.com) consisted of 67 amplicons targeting 14,642 bp, and generating a 250 bp paired-end sequence for each amplicon. The uniquely tagged amplicon library was used for cluster generation and sequencing. The sequence data was processed with RTA (v1.17.28 ) and analyzed using the TruSeq Amplicon application within the MiSeq Reporter software (v2.2.0). These alignments were fed in BAM format into bam2mpg (https://research.nhgri.nih.gov/software/bam2mpg/index.shtml), which calls genotypes at all covered positions using a probabilistic Bayesian algorithm (Most Probable Genotype, or MPG).
Genotypes with MPG score >= 10 were considered reliable (Teer et al., 2010) . The variants were annotated using Annovar (https://www.openbioinformatics.org/annovar/annovar_gene.html).
Variants detected in dbSNP (version 137), 1000 Genomes, NHLBI 6500ESP, ExAC, and HGMD are annotated. All variants, genotypes, and annotations are viewed using VarSifter (https://research. nhgri.nih.gov/software/VarSifter/). To be considered highly reliable, genotypes should have an MPG score of at least 10 and a score to coverage ratio greater than 0.5. Further details are reported in the online Supplementary Material.
arrayCGH
A custom CGH 12 × 135K Array was designed using NimbleDesign (NimbleGen, Madison, WI). The design, hybridization, and data analysis were as described previously (Flynn et al., 2014) .
SNP array
Genotyping was performed using the HumanOmniExpress (750,000 SNPs), HumanOmniExpressExome (1 M SNPs), or HumanOmni2.5 (2.5 M SNPs) beadchips. DNA analysis using these BeadChip kits (Illumina, Inc.) was as described earlier (Sood et al., 2016 ).
Multiplex ligation probe analysis
The SALSA MLPA probe mixes for FANCA, P031-B1 mix 1 and P032-B1 mix 2, were used to detect large deletions in FANCA (MRC-Holland, Amsterdam, the Netherlands). Seventy-five to 100 ng of genomic DNA in a volume of 5 l was used for each probe mix reaction. The denaturation, hybridization, ligation, and PCR reactions were performed using the protocol provided by MRC-Holland.
Cell lines
Cell lines were derived from individuals who had been diagnosed with FA and were registered in IFAR. BJ cells are normal foreskin fibroblasts obtained from ATCC. RA3087 cells are fibroblasts derived from a FA patient with biallelic deletions in FANCA , resulting in no expression of FANCA protein (Kim et al., 2013) .
Vectors and mutagenesis
The FANCA gene was amplified by polymerase chain reaction using LFAPEG (gift from Dr. Detlev Shindler) and cloned into pDONR223.
FANCA mutants were generated with the QuikChange II XL SiteDirected Mutagenesis kit (Agilent Technologies, Santa Clara, CA, USA) using mutagenesis primers. Mutants were recombined into pHAGE vector using LR clonase (Invitrogen, Grand Island, NY, USA). HPV E6 and E7 and hTERT expression plasmids were described previously (Kim et al., 2011) .
Antibodies
Anti-HA antibody (MMS-101R; Covance, San Diego, CA, USA) was used for immunofluorescence and Western blotting. Anti-GAPDH (25778; Santa Cruz, Dallas, TX, USA), and anti-FANCA (A301-980A; Bethyl, Montgomery, TX, USA) antibodies were used for Western blotting.
Immunofluorescence
Immunofluorescence was performed on human fibroblasts as described previously (Smogorzewska et al., 2007) . Cells were grown on coverslips and washed twice with PBS. Cells were pre-extracted with 0.1% Triton X-100 in PBS, fixed in 3.7% formaldehyde and permeabi- 
MMC sensitivity assay
2.5 × 10 4 cells were plated in each well of a six-well plate in triplicate.
Twenty-four hours later, MMC (M4287; Sigma, St. Louis, MO, USA) was added at final concentrations from 0 to 75 nM. After 3-4 days in culture, cells were split at appropriate dilutions and after total of 6-8 days in culture, cell numbers were counted with a Z2 Coulter counter (Beckman Coulter, Brea, CA, USA). The cell numbers at each dose of drug were divided by the cell number in the untreated sample to calculate percent survival.
RESULTS

High-throughput FANCA screening of 216 FA families
We screened 216 families diagnosed with FA, but whose associated pathogenic variants were unknown. The cohort included 87 families assigned to the FA-A group based on prior complementation tests and 129 families that had not been previously complementation tested (Figure 1 ). Using a variety of approaches, as described in section Methods and Table 1 , we identified two likely pathogenic variants in 79 of the 87 families known to be FA-A (Figure 1 ). In seven of the 87 families, only one putative pathogenic variant was identified. In one family, no FANCA mutations were found, but, rather, two putative pathogenic FANCE variants were observed. In 129 families without complementation testing, we found two mutations in 80 families and one mutation F I G U R E 1 A schematic presentation of 216 FA families screened for FANCA mutations with their complementation and mutation status after completion of the study. The 40 patients with one FANCA mutation known is based on previously performed screening for a couple of very common FA mutations or deletions by MLPA TA B L E 1 Number of patients carrying two pathogenic FANCA mutations and the methods employed to discover each mutation 
Identification and characterization of two variants in each of 159 FANCA families
Characteristics of FANCA variants identified in the 159 FA families are presented in Table 2 and Supp. (Table 3) . Among the previously identified missense variants, pathogenicity of some have been shown through functional analysis of engineered missense expression constructs or from RNA analysis of patient cell lines, and all by prediction programs (Supp . Table S3 ).
Evaluation of novel missense variants by functional assay
We identified 18 novel rare missense variants that were absent in dbSNP and FAMutDB. To confirm their pathogenicity, we performed functional analysis of all 18 variants by expressing a mutagenized we consider it to be most likely non-pathogenic. The p.R756C variant was expressed very poorly and although it was localized to the nucleus, staining was weak. Considering that the patient was homozygous for this variant and the patient's cells were clinically complemented by the FANCA cDNA, we consider this variant to be most likely pathogenic.
Aberrant splicing caused by two nonsynonymous variants and an intronic indel
FANCA variants, c.522G>C (predicted p.Q174H) and c.1565A>G (predicted p.K522R), were identified as second alleles in two patients (FAM117 and FAM89, respectively) who were assigned to the FA-A group by complementation. As described above, the p. 
Consequence of FANCA mutations on FANCA protein expression
We studied FANCA protein expression in a subset of patients from whom cell lines had been created ( Figure 4 ). As anticipated, the carriers whose two mutations belong to nonsense, indel, or large deletions showed none or low expression of FANCA protein (RA2227/FAM95, RA2357/FAM100, RA2448/FAM102, RA1535/FAM33, and RA1759/FAM46). In addition, RA2250/FAM96, with a large deletion and a codon 1 mutation, also lacks FANCA protein expression. Among the patient cell lines with FANCA expression F I G U R E 2 Functional assays of FANCA missense variants to determine pathogenicity. A: MMC sensitivity in FANCA-null RA3087/E6E7/hTERT cell lines expressing indicated FANCA variants. The two graphs represent two separate experiments. Empty vector (EV), wild-type (WT) FANCA, and FANCA mutant K522R was included in both experiments. Indicated cell lines were treated with increasing doses of MMC and total cell number was counted after 6-8 days. Values were normalized using untreated control to determine the percent survival of cells expressing the indicated variants. Cell lines for survival assays were plated in triplicate; error bars represent standard deviation. B: Immunoblot with anti-HA antibody to test expression levels of HA-tagged FANCA variants that were transduced into FANCA-null RA3087/E6E7/hTERT fibroblasts. The FANCA-null RA3087 cell line was derived from a FA patient with biallelic FANCA deletions (delEx9-43). C: Immunofluorescence to detect HA-tagged FANCA expressed in FANCA-null RA3087/E6E7/hTERT fibroblasts. Localization is categorized as being nuclear or cytoplasmic 
DISCUSSION
Several studies have reported mutations in the FANCA gene since the discovery of FANCA in 1996 (Apostolou et al., 1996; Lo Ten Foe et al., 1996) . This report includes the largest number of FANCA patients, and identifies both mutations in 159 patients. As the precise characterization of both disease-causing mutations in an FA patient is a prerequisite for genetic counseling and reliable correlation with the patient phenotype, multipronged approaches are required for molecular diagnosis.
A distinct set of FANCA mutations in nearly all FANCA families studied
A distinct set of mutations accounted for the disease in 152 out of 159 FA families, illustrating the exceptional genetic heterogeneity of FANCA mutations in FA patients (Table 2 ). Only two families had an identical pair of compound heterozygous mutations (FAM10 and FAM8) and in fact, we subsequently learned that they were related. Also, two distinct homozygous mutations were present in two and three families each: c. 2851C>T in FAM141 and FAM129, and c.1827-1G>A in FAM23, FAM138, and FAM107 . The complex heterogeneity is also apparent from the fact that we identified 48 distinct and novel variants accounting for 63 mutant alleles, of which none were homozygous, and no more than three families carried the same novel variant (Table 3) . However, our study adds seven and eleven more patients respectively to the list of two most often encountered FANCA variants in the FAMutDB, c.3788_3790delTCT (present 261 times), c.1115_1118delTTGG (present 67 times). We also add eleven more patients to the 19 known patients who carry the p.T1131A mutation, and four more to the known c.3624C>T list. The latter is predicted to be a synonymous variant, (p.S1208S) but causes aberrant splicing (Ameziane et al., 2008) . Eleven of the novel pathogenic variants were present in the ExAC database, but none were observed at a frequency greater than 0.009 (Table 3 ). Figure 5 illustrates their group can now be determined by methods described earlier (Chandrasekharappa et al., 2013) .
Large deletions account for nearly a quarter of all pathogenic variants in FANCA
Of the 318 mutant alleles, we observed 57 deletions in this study. We have reported previously ten FANCA families with biallelic deletions (Flynn et al., 2014) , and ten other families with a total of four deletions (Chandrasekharappa et al., 2013; Donovan et al., 2016) 2009), 25% (Ameziane et al., 2008) , and 40% (Morgan et al., 1999 
High-throughput and combinations of technologies ensure comprehensive mutation analysis
We employed high-throughput sequencing methodologies for vari- 
Evaluation of pathogenicity of nonsynonymous and intronic indel variants
The ability of a missense variant to complement the growth deficiency of a null cell is a standard and reliable assay to determine pathogenicity (or lack thereof). This functional evaluation helped identify eleven new pathogenic variants. However, two of the seven variants (c.522G>C
and c.1565A>G) that behaved as wild-type in functional assays, turned out to instead affect splicing. In both cases, the consensus AG exonic sequences at the splice junction where the U1 snRNA binds (AG|gtragt) are altered, CAG|gt > CAC|gt in exon 5 and AAG|gt > AGG|gt in exon 16, and thus, may prevent U1snRNP from performing its normal function (Cartegni, Chew, & Krainer, 2002) . We had observed earlier that altering the G in the wobble position (last) of the same codon in exon 16
in another patient (c.1566G>A; pK522K) produced exon 16 skipping as well (Chandrasekharappa et al., 2013) . We also report an intronic 
Pathogenic nonsynonymous variants are retained in the cytoplasm
All nonsynonymous variants that were shown to be pathogenic by functional analysis resided in the cytoplasm and, conversely, those categorized as nonpathogenic localized to the nucleus. Nuclear localization of FANCA protein is critical for normal biological function (Naf, Kupfer, Suliman, Lambert, & D'Andrea, 1998) . Impairment of nuclear localization by pathogenic missense variants has been recognized previously by several investigators (Adachi et al., 2002; Castella et al., 2011; Garcia-Higuera, Kuang, Denham, & D'Andrea, 2000) . The mechanism causing so many deleterious variants to localize erroneously in the cytoplasm is unexplored; however, a likely explanation is that the resultant proteins are inappropriately folded. Exploring ways to correct the impaired subcellular localization may lead to novel therapeutic approaches. A recent report indicates that relative levels of interaction between the FANCA mutant proteins with chaperonins HSP90
and HSP70 can directly contribute to the clinical course of the disease (Karras et al., 2017) . It remains to be tested if FANCA variants can localize appropriately to the nucleus following upregulation of HSP90 activity.
Final remarks
Identification of the precise molecular nature of variants at the genomic level is a prerequisite for efficient clinical management of FA patients, genetic counseling for families, understanding the disease process to explore novel therapeutic options, and discovery of genotype-phenotype correlations with prognostic implications. The enrollment of these patients in registries, such as the IFAR, enables us to obtain the patient-derived cell lines and RNA necessary for functional analysis of FA variants, thereby confirming their pathogenicity, or lack thereof, which is especially important for genes like FANCA which exhibit complex heterogeneity. This ensures the correct diagnosis is given, and allows for accurate carrier and prenatal testing.
